| Literature DB >> 35008826 |
Maria Minodora Marin1,2, Raluca Ianchis3, Rebeca Leu Alexa1, Ioana Catalina Gifu3, Madalina Georgiana Albu Kaya2, Diana Iulia Savu4, Roxana Cristina Popescu4, Elvira Alexandrescu3, Claudia Mihaela Ninciuleanu3, Silviu Preda5, Madalina Ignat2, Roxana Constantinescu2, Horia Iovu1,6.
Abstract
The fabrication of collagen-based biomaterials for skin regeneration offers various challenges for tissue engineers. The purpose of this study was to obtain a novel series of composite biomaterials based on collagen and several types of clays. In order to investigate the influence of clay type on drug release behavior, the obtained collagen-based composite materials were further loaded with gentamicin. Physiochemical and biological analyses were performed to analyze the obtained nanocomposite materials after nanoclay embedding. Infrared spectra confirmed the inclusion of clay in the collagen polymeric matrix without any denaturation of triple helical conformation. All the composite samples revealed a slight change in the 2-theta values pointing toward a homogenous distribution of clay layers inside the collagen matrix with the obtaining of mainly intercalated collagen-clay structures, according X-ray diffraction analyses. The porosity of collagen/clay composite biomaterials varied depending on clay nanoparticles sort. Thermo-mechanical analyses indicated enhanced thermal and mechanical features for collagen composites as compared with neat type II collagen matrix. Biodegradation findings were supported by swelling studies, which indicated a more crosslinked structure due additional H bonding brought on by nanoclays. The biology tests demonstrated the influence of clay type on cellular viability but also on the antimicrobial behavior of composite scaffolds. All nanocomposite samples presented a delayed gentamicin release when compared with the collagen-gentamicin sample. The obtained results highlighted the importance of clay type selection as this affects the performances of the collagen-based composites as promising biomaterials for future applications in the biomedical field.Entities:
Keywords: biomaterials; clay; type II collagen
Mesh:
Substances:
Year: 2021 PMID: 35008826 PMCID: PMC8745677 DOI: 10.3390/ijms23010401
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Scheme 1Schematic structures of the different types of mineral clays.
Figure 1FTIR spectra of the obtained collagen/clay composite biomaterials.
Figure 2X-ray diffraction patterns of composite samples.
Figure 3SEM images of collagen/clay composite biomaterials (250×) and calculated average pore diameter with standard deviation.
Figure 4TGA curves of collagen/clay composite biomaterials.
Thermogravimetric properties of the collagen/clay composite biomaterials.
| Sample | T10% (°C) | T50% (°C) | Water Loss Step | Thermal Degradation Step | Residual Mass (%) |
|---|---|---|---|---|---|
| Tmax% (°C) | Tmax% (°C) | ||||
| Coll | 257.6 | 348.5 | 56.3 | 319.3 | 23.82 |
| Coll-ClNa | 263.7 | 393.2 | 64.8 | 327.2 | 37.59 |
| Coll-Cl30B | 271.6 | 372.7 | 61.0 | 326.1 | 33.51 |
| Coll-Cl93A | 271.2 | 364.2 | 64.3 | 329.0 | 30.44 |
| Coll-Cl20A | 259.0 | 359.7 | 56.3 | 326.6 | 29.41 |
| Coll-Cl15A | 262.7 | 357.6 | 58.7 | 326.5 | 29.76 |
Figure 5Equilibrium swelling degree of collagen-based samples (ns p > 0.05, ** p ≤ 0.01).
Figure 6Biodegradation degree as function of time for the composite samples: (a). third day; (b). 7th day, (c). 17th day; (d). 50th day (ns p > 0.05, * p ≤ 0.05, ** p ≤ 0.01).
Figure 7DMA mechanical properties of dried collagen/clay composite biomaterials.
Behavior of dried samples under stress applied. Revert to the initial form after stress condition.
| Sample | Sample Distortion under Stress Condition (Force Applied = 5 N), (%) | Revert after 10 s, (%) | Revert after 30 min, (%) |
|---|---|---|---|
| Coll | 62.79 | 56.45 | 88.02 |
| Coll-ClNa | 20.99 | 90.66 | 99.12 |
| Coll-Cl30B | 25.68 | 89.95 | 94.34 |
| Coll-Cl93A | 49.80 | 68.15 | 90.52 |
| Coll-Cl20A | 58.63 | 85.12 | 93.80 |
| Coll-Cl15A | 56.08 | 56.45 | 88.02 |
Figure 8DMA stress–strain curves for the collagen/clay composite hydrogels swollen in PBS.
Figure 9Gentamicin release profile as a function of time.
Figure 10Antimicrobial activity against Escherichia coli and Staphylococcus aureus.
Evaluation of the antimicrobial activity of the composite samples loaded with gentamicin.
| Sample | Inhibition Area (mm) | Bacterial Strain | Evaluation | SD (Standard Deviation) |
|---|---|---|---|---|
| Coll | Absent |
| Insufficient effect | 0 |
| Absent |
| Insufficient effect | 0 | |
| G-Coll | 10 |
| Satisfactory effect | 0.3 |
| 11 |
| Satisfactory effect | 0.1 | |
| G-Coll-ClNa | 7.5 |
| Satisfactory effect | 0.1 |
| 8.5 |
| Satisfactory effect | 0.1 | |
| G-Coll-Cl30B | 6 |
| Satisfactory effect | 0.1 |
| 5 |
| Satisfactory effect | 0.1 | |
| G-Coll-Cl93A | 9.5 |
| Satisfactory effect | 0.1 |
| 3.5 |
| Satisfactory effect | 0.1 | |
| G-Coll-Cl20A | 10.5 |
| Satisfactory effect | 0.1 |
| 9 |
| Satisfactory effect | 0.2 | |
| G-Coll-Cl15A | 10 |
| Satisfactory effect | 0.1 |
| 6 |
| Satisfactory effect | 0.1 |
Figure 11Biological evaluation of the obtained samples, *** p ≤ 0.001.
The composition of the new collagen/clay composite biomaterials.
| Sample | Collagen (%) | ClNa | Cl30B | Cl93A | Cl20A | Cl15A | Gentamicin (GE) (%) | GA (%) |
|---|---|---|---|---|---|---|---|---|
| Coll | 1.5 | - | - | - | - | - | - | 0.16 |
| Coll-ClNa | 1.5 | 0.375 | - | - | - | - | - | 0.16 |
| Coll-Cl30B | 1.5 | - | 0.375 | - | - | - | - | 0.16 |
| Coll-Cl93A | 1.5 | - | - | 0.375 | - | 0.16 | ||
| Coll-Cl20A | 1.5 | - | - | - | 0.375 | - | 0.16 | |
| Coll-Cl15A | 1.5 | - | - | - | - | 0.375 | - | 0.16 |
| G-Coll | 1.5 | - | - | - | - | - | 0.2 | 0.16 |
| G-Coll-ClNa | 1.5 | 0.375 | - | - | - | - | 0.2 | 0.16 |
| G-Coll-Cl30B | 1.5 | - | 0.375 | - | - | - | 0.2 | 0.16 |
| G-Coll-Cl93A | 1.5 | - | - | 0.375 | - | - | 0.2 | 0.16 |
| G-Coll-Cl20A | 1.5 | - | - | - | 0.375 | - | 0.2 | 0.16 |
| G-Coll-Cl15A | 1.5 | - | - | - | - | 0.375 | 0.2 | 0.16 |
All the percentages are reported to 100 g sample.
Figure 12Obtained collagen/clay composite biomaterials (without gentamicin).